HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare (Apr.13) - Trump's Tariffs on Pharmaceuticals, NSCEB's Report, RemeGen's Pain Point

Pre-IPO Chagee Holdings - IPO Pricing Is Attractive, But Share Price May Underperform

Pre-IPO Chagee Holdings - The Business Model, the Concerns Behind and Valuation Outlook

MIXUE Group (2097.HK) - Updates on Performance Forecast and Valuation Outlook

Mixue Group (2097 HK) - Updates on Valuation Outlook and Growth Forecast Based on 2024 Results

Equity Capital Markets

<ul>
<li>The main reason behind declining performance is related to the increase in regional market density brought about by newly opened teahouses. Franchisees would be more cautious about investing in Chagee.</li>
<li>With the passage of time and the declining same store GMV, the low teahouse closure rate will gone. Product strategy of "flagship product + classic basics " also has risks.</li>
<li>Based on our forecast of 2025 net profit of about RMB3 billion (or US$400 million) and US IPO market value of US$5 billion, P/E is about 12.5x. </li>
</ul>


The main reason behind declining performance is related to the increase in regional market density brought about by newly opened teahouses. Franchisees would be more cautious about investing in Chagee.
With the passage of time and the declining same store GMV, the low teahouse closure rate will gone. Product strategy of "flagship product + classic basics " also has risks.
Based on our forecast of 2025 net profit of about RMB3 billion (or US$400 million) and US IPO market value of US$5 billion, P/E is about 12.5x. 


Pre-IPO Chagee Holdings - Some Points Worth the Attention